Myopathic Ehlers-Danlos Syndrome · mEDS

Description

Myopathic Ehlers-Danlos syndrome, mEDS, is a rare connective tissue disorder caused by pathogenic variants in COL12A1, the gene that encodes type XII collagen. Type XII collagen is a member of the FACIT family, fibril-associated collagens with interrupted triple helices, that decorates the surface of large collagen fibrils and organizes the interface between fibrillar collagen and surrounding muscle and tendon. Loss of normal type XII collagen disrupts that interface, and the clinical picture sits at the intersection of a collagen disorder and a congenital myopathy.

The 2017 international classification of the Ehlers-Danlos syndromes (Malfait et al., American Journal of Medical Genetics Part C, 2017) sets three major criteria for mEDS: congenital muscle hypotonia or muscle atrophy that improves with age, proximal joint contractures including knee, hip, and elbow, and hypermobility of distal joints. Minor criteria include soft, doughy skin, atrophic scarring, motor delay, and myopathy on muscle biopsy. Molecular confirmation requires a heterozygous or biallelic pathogenic variant in COL12A1.

Inheritance is reported as both autosomal dominant and autosomal recessive at the same gene. Dominant cases involve dominant-negative variants, where one altered chain disrupts the type XII collagen trimer. Recessive cases involve biallelic loss-of-function variants and tend toward a more severe presentation. The split illustrates a dose-effect pattern at COL12A1 that the 2017 framework treats as one disorder with two inheritance modes.

Fewer than 30 affected individuals have been reported in the medical literature since the first COL12A1 description by Hicks et al. (Annals of Neurology, 2014) and Zou et al. (Human Molecular Genetics, 2014). Prevalence estimates are not reliable at this case count.

Treatments to date

No drug therapy targets COL12A1 or type XII collagen. Care is supportive and proceeds along two parallel tracks, the muscle track and the joint track, coordinated by a clinician familiar with both congenital myopathy and connective tissue disease.

Physical therapy and occupational therapy are the standard of care from infancy. Early intervention focuses on motor milestones delayed by hypotonia and proximal weakness. Strengthening continues through childhood, with attention to the proximal muscles of the shoulder and hip girdle. Distal joint hypermobility coexists with this proximal weakness, and bracing or activity modification is often used to protect hyperextensible knees, ankles, and small joints during the years of greatest joint laxity.

Proximal contractures of the elbows, hips, and knees develop or worsen with age in many affected individuals. Stretching programs, serial casting, and orthotic management address contractures conservatively. Surgical release is considered for fixed contractures that limit function. Outcomes from contracture surgery in mEDS specifically are not described in cohort studies given the small number of reported cases, and decisions draw on the broader congenital myopathy literature.

Cardiac and aortic surveillance is not part of the standard mEDS workup, in contrast to vascular and classical EDS subtypes. Skin care follows the general EDS playbook of wound protection, atrophic scar management, and care during procedures. Anesthetic planning accounts for hypotonia and possible respiratory muscle involvement.

No clinical trials of disease-modifying therapy in mEDS were registered as of the most recent reviews. Research priorities named by the EDS subtype working groups include natural history data on contracture progression, muscle biopsy correlation with COL12A1 genotype, and whether the dominant and recessive forms differ enough at the bedside to warrant separate diagnostic categories in future revisions of the international classification.